7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same
申请人:GREEN CROSS CORPORATION
公开号:US10239873B2
公开(公告)日:2019-03-26
Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.
本研究提供了作为 IKKε(I-kappa-B 激酶ε)和 TBK1(TANK 结合激酶 1)
抑制剂的
7-氮杂吲哚或
4,7-二氮杂吲哚衍
生物。胃癌、肝癌、皮肤癌、肺癌、脑癌、膀胱癌、食道癌、胰腺癌、甲状腺癌、头颈部癌、鳞状细胞癌、骨肉瘤、B 细胞或 T 细胞淋巴瘤、急性或慢性白血病和多发性骨髓瘤,但也可作为慢性炎症的治疗剂。